Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma

References

• Mirnezami R, Mehta AM, Chandrakumaran K, et al. (2014). Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer 111:1500–8.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Bruin S, Boot H, et al. (2008). 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426–32.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Ruth S, de Bree E, et al. (2003). Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–43.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Cabras AD, et al. (2013). Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 49:3140–8.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Lianos E, et al. (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22:1570–5.
   PubMed Web of Science ®Google Scholar
• Marcotte E, Dube P, Drolet P, et al. (2014). Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis. World J Surg Oncol 12:332.
   PubMed Web of Science ®Google Scholar
• Sideris L, Mitchell A, Drolet P, et al. (2009). Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. Can J Surg 52:135–41.
   PubMed Web of Science ®Google Scholar
• Yan TD, Deraco M, Baratti D, et al. (2009). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–42.
   PubMed Web of Science ®Google Scholar
• Glehen O, Gilly FN, Arvieux C, et al. (2010). Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17:2370–7.
   PubMed Web of Science ®Google Scholar
• Gonzalez Bayon L, Steiner MA, Vasquez Jimenez W, et al. (2013). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? Eur J Surg Oncol 39:1109–15.
   PubMed Web of Science ®Google Scholar
• Glehen O, Gilly FN, Boutitie F, et al. (2010). Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116:5608–18.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. (2006). New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7:69–76.
   PubMed Web of Science ®Google Scholar
• Esquivel J, Piso P, Verwaal V, et al. (2014). American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol 110:777–8.
   PubMed Web of Science ®Google Scholar
• Bakrin N, Bereder JM, Decullier E, et al. (2013). Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 39:1435–43.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. (2012). Parietal peritonectomy. Ann Surg Oncol 19:1250
   PubMed Web of Science ®Google Scholar
• Sugarbaker P. (2012). Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy: textbook and video atlas. Woodbury, CT: Ciné-Med Publishing. p. 214.
   Google Scholar
• Van der Speeten K, Stuart OA, Sugarbaker PH. (2012). Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy. Surg Oncol Clin N Am 21:577–97.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Graves T, DeBruijn EA, et al. (1990). Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res 50:5790–4.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Mora JT, Carmignani P, et al. (2005). Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 10:112–22.
   PubMed Web of Science ®Google Scholar
• Mahteme H, von Heideman A, Grundmark B, et al. (2008). Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis. Eur J Surg Oncol 34:547–52.
   PubMed Web of Science ®Google Scholar
• Cashin PH, Mahteme H, Graf W, et al. (2013). Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer. BMC Cancer 13:435.
   PubMed Web of Science ®Google Scholar
• Levine EA, Blazer DG III, Kim MK, et al. (2012). Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg 214:599–606. Discussion 7.
   PubMed Web of Science ®Google Scholar
• Fujishima Y, Goi T, Kimura Y, et al. (2012). MUC2 protein expression status is useful in assessing the effects of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon cancer. Int J Oncol 40:960–4.
   PubMed Web of Science ®Google Scholar
• Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. (1978). Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11.
   PubMedGoogle Scholar
• Rubin J, Clawson M, Planch A, Jones Q. (1988). Measurements of peritoneal surface area in man and rat. Am J Med Sci 295:453–8.
   PubMed Web of Science ®Google Scholar
• Elias DM, Sideris L. (2003). Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 12:755–69.
   PubMedGoogle Scholar
• Sugarbaker PH, Stuart OA, Carmignani CP. (2006) Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 57:703–8.
   PubMed Web of Science ®Google Scholar
• Mas-Fuster MI, Ramon-Lopez A, Nalda-Molina R. (2013). Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): a pharmacodynamic point of view. Cancer Chemother Pharmacol 72:273–4.
   PubMed Web of Science ®Google Scholar
• Van der Speeten K, Stuart OA, Chang D, et al. (2011). Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 68:147–56.
   PubMed Web of Science ®Google Scholar
• Elias D, Lefevre JH, Chevalier J, et al. (2009). Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27:681–5.
   PubMed Web of Science ®Google Scholar
• Franko J, Ibrahim Z, Gusani NJ, et al. (2010). Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 116:3756–62.
   PubMed Web of Science ®Google Scholar
• Elias D, Bonnay M, Puizillou JM, et al. (2002). Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:267–72.
   PubMed Web of Science ®Google Scholar
• Glehen O, Kwiatkowski F, Sugarbaker PH, et al. (2004). Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–92.
   PubMed Web of Science ®Google Scholar
• Yan TD, Black D, Savady R, Sugarbaker PH. (2006). Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24:4011–19.
   PubMed Web of Science ®Google Scholar
• Yan TD, Welch L, Black D, Sugarbaker PH. (2007). A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18:827–34.
   PubMed Web of Science ®Google Scholar
• Yan TD, Black D, Sugarbaker PH, et al. (2007). A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14:2702–13.
   PubMed Web of Science ®Google Scholar
• Bijelic L, Jonson A, Sugarbaker PH. (2007). Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol 18:1943–50.
   PubMed Web of Science ®Google Scholar
• Helm CW, Richard SD, Pan J, et al. (2010). Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer 20:61–9.
   PubMed Web of Science ®Google Scholar
• Klaver CE, Musters GD, Bemelman WA, et al. (2015). Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer 15:428.
   PubMed Web of Science ®Google Scholar
• Los G, Mutsaers PH, van der Vijgh WJ, et al. (1989). Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49:3380–4.
   PubMed Web of Science ®Google Scholar
• Conti M, De Giorgi U, Tazzari V, et al. (2004). Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. J Chemother 16(Suppl 5):23–5.
   PubMed Web of Science ®Google Scholar
• Gladieff L, Chatelut E, Dalenc F, Ferron G. (2009). [Pharmacological bases of intraperitoneal chemotherapy]. Bull Cancer 96:1235–42.
   PubMed Web of Science ®Google Scholar
• Coccolini F, Cotte E, Glehen O, et al. (2014). Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol 40:12–26.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Hannigan EV, et al. (1996). Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–5.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43.
   PubMed Web of Science ®Google Scholar
• Zivanovic O, Abramian A, Kullmann M, et al. (2014). HIPEC ROC I: A phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer 136:699–708.
   PubMed Web of Science ®Google Scholar
• Hakeam HA, Breakiet M, Azzam A, et al. (2014). The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail 36:1486–91.
   PubMed Web of Science ®Google Scholar
• Urano M, Kuroda M, Nishimura Y. (1999). For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 15:79–107.
   PubMed Web of Science ®Google Scholar
• Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. (2011). Pharmacokinetic study of perioperative intravenous Ifosfamide. Int J Surg Oncol 2011:185092.
   PubMedGoogle Scholar
• Deraco M, Baratti D, Cabras AD, et al. (2010). Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol 2:76–84.
   PubMed Web of Science ®Google Scholar
• Stewart JHt, Shen P, Russell G, et al. (2008). A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol 15:2137–45.
   PubMed Web of Science ®Google Scholar
• Elias D, Raynard B, Bonnay M, Pocard M. (2006). Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies. Eur J Surg Oncol 32:607–13.
   PubMed Web of Science ®Google Scholar
• Piche N, Leblond FA, Sideris L, et al. (2011). Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg 254:138–44.
   PubMed Web of Science ®Google Scholar
• Elias D, El Otmany A, Bonnay M, et al. (2002). Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 63:346–52.
   PubMed Web of Science ®Google Scholar
• Smith E, Brock AP. (1989). The effect of reduced osmolarity on platinum drug toxicity. Br J Cancer 59:873–5.
   PubMed Web of Science ®Google Scholar
• Pomel C, Ferron G, Lorimier G, et al. (2010). Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol 36:589–93.
   PubMed Web of Science ®Google Scholar
• Chalret du Rieu Q, White-Koning M, Picaud L, et al. (2014). Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother Pharmacol 74:571–82.
   PubMed Web of Science ®Google Scholar
• Charrier T, Passot G, Peron J, et al. (2016). Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol 23:2315–22.
   PubMed Web of Science ®Google Scholar
• De Somer F, Ceelen W, Delanghe J, et al. (2008). Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 28:61–6.
   PubMed Web of Science ®Google Scholar
• Jerremalm E, Hedeland M, Wallin I, et al. (2004). Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 21:891–4.
   PubMed Web of Science ®Google Scholar
• Mehta AM, Van den Hoven JM, Rosing H, et al. (2015). Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm 479:23–7.
   PubMed Web of Science ®Google Scholar
• Bachur NR, Gordon SL, Gee MV, Kon H. (1979). NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 76:954–7.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Averbach A, Stephens AD, et al. (1998). Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology 55:130–8.
   PubMed Web of Science ®Google Scholar
• Fujita T, Tamura T, Yamada H, et al. (1997). Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice. J Drug Target 4:289–96.
   PubMed Web of Science ®Google Scholar
• Mohamed F, Cecil T, Moran B, Sugarbaker P. (2011). A new standard of care for the management of peritoneal surface malignancy. Curr Oncol 18:e84–96.
   PubMed Web of Science ®Google Scholar
• Levine EA, Stewart JHt, Shen P, et al. (2014). Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg 218:573–85.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Corry PM, Drewinko B. (1980). In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40:1165–8.
   PubMed Web of Science ®Google Scholar
• de Bree E, Tsiftsis DD. (2007). Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside recent results. Cancer Res 169:53–73.
   Google Scholar
• van Ruth S, Verwaal VJ, Zoetmulder FA. (2003). Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 12:771–80.
   PubMedGoogle Scholar
• Witkamp A. (1998). Dose finding study of hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with carcinosis of colorectal origin. Eur J Surg Oncol 24:214.
   Google Scholar
• Turaga K, Levine E, Barone R, et al. (2014). Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 21:1501–5.
   PubMed Web of Science ®Google Scholar
• Tritton TR. (1991). Cell surface actions of adriamycin. Pharmacol Ther 49:293–309.
   PubMed Web of Science ®Google Scholar
• Triton TR, Yee G. (1982). The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 217:248–50.
   PubMed Web of Science ®Google Scholar
• Lane P, Vichi P, Bain DL, Tritton TR. (1987). Temperature dependence studies of adriamycin uptake and cytotoxicity. Cancer Res 47:4038–42.
   PubMed Web of Science ®Google Scholar
• Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. (2009). A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol 63:799–805.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Young RC, Speyer JL, et al. (1982). Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42:4265–9.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Locker GY, Doroshow JH, et al. (1979). Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39:3209–14.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Locker GY, Doroshow JH, et al. (1979). Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin. Cancer Treat Rep 63:269–73.
   PubMedGoogle Scholar
• Nagai K, Nogami S, Egusa H, Konishi H. (2014). Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats. Pharmazie 69:125–7.
   PubMed Web of Science ®Google Scholar
• Pilati P, Mocellin S, Rossi CR, et al. (2003). Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma. World J Surg 27:640–6.
   PubMed Web of Science ®Google Scholar
• Rossi CR, Foletto M, Mocellin S, et al. (2002). Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 94:492–9.
   PubMed Web of Science ®Google Scholar
• Harrison LE, Bryan M, Pliner L, Saunders T. (2008). Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Ann Surg Oncol 15:1407–13.
   PubMed Web of Science ®Google Scholar
• Salvatorelli E, De Tursi M, Menna P, et al. (2012). Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis. Drug Metab Dispos 40:2365–73.
   PubMed Web of Science ®Google Scholar
• Moran B, Cecil T, Chandrakumaran K, et al. (2015). The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis 17:772–8.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Van der Speeten K, Anthony Stuart O, Chang D. (2011). Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur J Surg Oncol 37:719–26.
   PubMed Web of Science ®Google Scholar
• Ansaloni L, Agnoletti V, Amadori A, et al. (2012). Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 22:778–85.
   PubMed Web of Science ®Google Scholar
• Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. (2010). Pharmacology of perioperative 5-fluorouracil. J Surg Oncol 102:730–5.
   PubMed Web of Science ®Google Scholar
• Elias D, Benizri E, Di Pietrantonio D, et al. (2007). Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 14:509–14.
   PubMed Web of Science ®Google Scholar
• McConnell YJ, Mack LA, Francis WP, et al. (2013). HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol;107:591–6.
   PubMed Web of Science ®Google Scholar
• Tan GH, Ong WS, Chia CS, et al. (2016). Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference? Int J Hyperthermia 32:281–8.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Welch LS, Mohamed F, Glehen O. (2003). A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 12:605–21.
   PubMedGoogle Scholar
• Heidelberger C, Chaudhuri NK, Danneberg P, et al. (1957). Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179:663–6.
   PubMed Web of Science ®Google Scholar
• Muggia FM, Peters GJ, Landolph JR. Jr. (2009). XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther 8:992–9.
   PubMedGoogle Scholar
• Wagner PL, Jones D, Aronova A, et al. (2012). Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis. Dis Colon Rectum 55:407–15.
   PubMed Web of Science ®Google Scholar
• Yu W, Whang I, Chung HY, et al. (2001). Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 25:985–90.
   PubMed Web of Science ®Google Scholar
• Kwon OK, Chung HY, Yu W. (2014). Early postoperative intraperitoneal chemotherapy for macroscopically serosa-invading gastric cancer patients. Cancer Res Treat 46:270–9.
   PubMed Web of Science ®Google Scholar
• Passot G, Vaudoyer D, Villeneuve L, et al. (2016). What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol 113:796–803.
   PubMed Web of Science ®Google Scholar
• Rohena CC, Mooberry SL. (2014). Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities. Nat Prod Rep 31:335–55.
   PubMed Web of Science ®Google Scholar
• de Bree E, Theodoropoulos PA, Rosing H, et al. (2006). Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Res 32:471–82.
   Google Scholar
• Mohamed F, Sugarbaker PH. (2003). Intraperitoneal taxanes. Surg Oncol Clin N Am 12:825–33.
   PubMedGoogle Scholar
• De Smet L, Ceelen W, Remon JP, Vervaet C. (2013). Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. Scientific World J 2013:720858.
   Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. (1996). Peritoneal-plasma barrier. Cancer Treat Res 82:53–63.
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell 144:646–74.
   PubMed Web of Science ®Google Scholar
• Lee S, Chen TT, Barber CL, et al. (2007). Autocrine VEGF signaling is required for vascular homeostasis. Cell 130:691–703.
   PubMed Web of Science ®Google Scholar
• De Falco S, Gigante B, Persico MG. (2002). Structure and function of placental growth factor. Trends Cardiovasc Med 12:241–6.
   PubMed Web of Science ®Google Scholar
• Gremonprez F, Descamps B, Izmer A, et al. (2015). Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model. Oncotarget 6:29889–900.
   PubMed Web of Science ®Google Scholar
• Kesterson JP, Mhawech-Fauceglia P, Lele S. (2008). The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol 111:527–9.
   PubMed Web of Science ®Google Scholar
• Hamilton CA, Maxwell GL, Chernofsky MR, et al. (2008). Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 111:530–2.
   PubMed Web of Science ®Google Scholar
• Choe JH, Overman MJ, Fournier KF, et al. (2015). Improved survival with anti-VEGF therapy in the treatment of unresectable appendiceal epithelial neoplasms. Ann Surg Oncol 22:2578–84.
   PubMed Web of Science ®Google Scholar
• Botrel TE, Clark LG, Paladini L, Clark OA. (2016). Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer 16:677.
   PubMed Web of Science ®Google Scholar
• Oliva P, Decio A, Castiglioni V, et al. (2012). Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. Br J Cancer 107:360–9.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, et al. (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–19.
   PubMed Web of Science ®Google Scholar
• Willaert W, Van Der Speeten K, Liberale G, Ceelen W. (2015). BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis. BMC Cancer 15:980.
   PubMed Web of Science ®Google Scholar
• Passot G, Bakrin N, Garnier L, et al. (2014). Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: the first step before intraperitoneal anti-vascular endothelial growth factor treatment? Eur J Cancer 50:722–30.
   PubMed Web of Science ®Google Scholar
• Chia CS, Glehen O, Bakrin N, et al. (2015). Intraperitoneal vascular endothelial growth factor: a prognostic factor and the potential for intraperitoneal bevacizumab use in peritoneal surface malignancies. Ann Surg Oncol 22(Suppl 3):S880–7.
   PubMed Web of Science ®Google Scholar
• Eveno C, Passot G, Goere D, et al. (2014). Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 21:1792–800.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. (2015). Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis. Crit Rev Oncol Hematol 93:127–35.
   PubMed Web of Science ®Google Scholar
• Pettigrew M, Kavan P, Surprenant L, Lim HJ. (2016). Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada. J Med Econ 19:135–47.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Bandou E, Sawa T, et al. (2006). Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol 32:661–5.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. (1996). Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. Cancer Treat Res 82:317–25.
   PubMedGoogle Scholar
• Zylberberg B, Dormont D, Janklewicz S, et al. (2001). Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. Eur J Gynaecol Oncol 22:40–5.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Elnemr A, Endou Y, et al. (2012). Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol 2012:148420.
   PubMedGoogle Scholar
• Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. (1993). Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 113:631–6.
   PubMed Web of Science ®Google Scholar
• Tempfer CB. (2015). Pressurized intraperitoneal aerosol chemotherapy as an innovative approach to treat peritoneal carcinomatosis. Med Hypotheses 85:480–4.
   PubMed Web of Science ®Google Scholar
• Solass W, Hetzel A, Nadiradze G, et al. (2012). Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 26:1849–55.
   PubMed Web of Science ®Google Scholar
• Solass W, Herbette A, Schwarz T, et al. (2012). Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc 26:847–52.
   PubMed Web of Science ®Google Scholar
• Solass W, Kerb R, Murdter T, et al. (2014). Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 21:553–9.
   PubMed Web of Science ®Google Scholar
• Solass W, Giger-Pabst U, Zieren J, Reymond MA. (2013). Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol 20:3504–11.
   PubMed Web of Science ®Google Scholar
• Tempfer CB, Winnekendonk G, Solass W, et al. (2015). Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol 137:223–8.
   PubMed Web of Science ®Google Scholar
• Blanco A, Giger-Pabst U, Solass W, et al. (2013). Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol 20:2311–16.
   PubMed Web of Science ®Google Scholar
• Robella M, Vaira M, De Simone M. (2016). Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol 14:128.
   PubMed Web of Science ®Google Scholar
• Khosrawipour V, Khosrawipour T, Diaz-Carballo D, et al. (2016). Exploring the spatial drug distribution Pattern of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Ann Surg Oncol 23:1220–4.
   PubMed Web of Science ®Google Scholar
• Demtroder C, Solass W, Zieren J, et al. (2016). Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis 18:364–71.
   PubMed Web of Science ®Google Scholar
• Tempfer CB, Solass W, Buerkle B, Reymond MA. (2014). Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report. Gynecol Oncol Rep 10:32–5.
   PubMedGoogle Scholar
• Kakchekeeva T, Demtroder C, Herath NI, et al. (2016). In vivo feasibility of electrostatic precipitation as an adjunct to Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC). Ann Surg Oncol 23:S592–8.
   PubMed Web of Science ®Google Scholar
• Dakwar GR, Shariati M, Willaert W, et al. (2016). Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis – mission possible? Adv Drug Deliv Rev 108:13–24.
   PubMed Web of Science ®Google Scholar
• De Smet L, Colin P, Ceelen W, et al. (2012). Development of a nanocrystalline Paclitaxel formulation for HIPEC treatment. Pharm Res 29:2398–406.
   PubMed Web of Science ®Google Scholar
• Xu S, Fan H, Yin L, et al. (2016). Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis. Eur J Pharm Biopharm 104:251–9.
   PubMed Web of Science ®Google Scholar
• Fujiware K, Armstrong D, Morgan M, et al. (2007). Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 17:1–20.
   PubMed Web of Science ®Google Scholar